Standout Papers

Venetoclax Plus Gilteritinib for <i>FLT3</i>-Mutated Relapsed/Refractory Acute Myeloid Leukemia 2022 2026 2023 2024115
  1. Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia (2022)
    Naval Daver, Alexander E. Perl et al. Journal of Clinical Oncology

Citation Impact

2 by Nobel laureates 9 from Science/Nature 55 standout
Sub-graph 1 of 23

Citing Papers

Inhibition of fatty acid oxidation enables heart regeneration in adult mice
2023 StandoutNature
Acute myeloid leukaemia
2023 Standout
4 intermediate papers

Works of Monique Dail being referenced

Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine
2021
Cytogenetic and Molecular Drivers of Outcome with Venetoclax-Based Combination Therapies in Treatment-Naïve Elderly Patients with Acute Myeloid Leukemia (AML)
2018
and 3 more

Author Peers

Author Hematology Molecular Biology Genetics CMN Last Decade Papers Cites
Monique Dail 841 823 246 274 48 1.4k
Jacek Kluska 14 19 236
Luciane Cristina Ouriques 44 39 601
Hasane Ratni 1 434 268 55 21 584
Peter C. Perdue 2 49 1.4k
J. E. Amonette 1 6 1 14 385

All Works

Loading papers...

Rankless by CCL
2026